Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07549412 · ClinicalTrials.gov registry record · Phase 3
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
A Phase 3 study, sponsored by EMD Serono Research & Development Institute.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,020
- Enrollment target
NCT07549412 is a Phase 3 study that is actively recruiting participants, run by EMD Serono Research & Development Institute. The registered enrollment target is 1,020 participants.
The verdict
NCT07549412, a Phase 3 study, is actively recruiting participants, sponsored by EMD Serono Research & Development Institute.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,020 participants
- Enrollment target
Study Summary
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluoride/tipiracil (FTD-TPI) plus bevacizumab.
Interventions
- DRUG Bevacizumab
- DRUG Precemtabart tocentecan
- DRUG Trifluridine/Tipiracil (FTD-TPI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,020 participants |
| Start Date | 2026-05-06 |
| Est. Completion | 2029-10-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07549412
The ClinicalTrials.gov registry entry for NCT07549412 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,020 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT07549412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07549412 about?
NCT07549412 is a clinical study titled "A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)". This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) a...
What is the current status of trial NCT07549412?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,020 participants. The study started on 2026-05-06. Estimated completion is 2029-10-16.
What interventions are being tested in trial NCT07549412?
The interventions under investigation include: Bevacizumab (DRUG), Precemtabart tocentecan (DRUG), Trifluridine/Tipiracil (FTD-TPI) (DRUG).
Who is sponsoring clinical trial NCT07549412?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.